Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (AMGN) is a global biotechnology leader pioneering innovative therapies for serious illnesses. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's latest developments, regulatory milestones, and strategic initiatives.
Track critical updates across Amgen's core therapeutic areas including oncology treatments, inflammatory disease therapies, and rare disease solutions. Our curated feed includes earnings reports, clinical trial data, partnership announcements, and manufacturing updates - all sourced directly from official channels.
Key resources include timely coverage of FDA decisions, research breakthroughs in biologics and biosimilars, and analysis of market-moving events. Bookmark this page for structured access to Amgen's evolving pipeline and business strategies without promotional bias.
Amgen will release its first quarter financial results on April 27, 2023, post market closure. The announcement will be followed by a conference call at 1:30 p.m. PT, featuring CEO Robert A. Bradway and senior management. Participants can access a live audio broadcast of the call, which will be available for replay for at least 90 days. Amgen, a leading biotechnology firm with a rich pipeline of medicines, was recognized in 2022 by Forbes as one of the "World's Best Employers" and by Barron's as one of "America's 100 Most Sustainable Companies." The company is part of both the Dow Jones Industrial Average and the Nasdaq-100 index.
Amgen announced that the U.S. Court of Appeals for the Federal Circuit upheld the validity of its patent for Otezla (apremilast), which is set to expire in February 2028. This ruling affirms a previous injunction preventing Sandoz and Zydus Pharmaceuticals from producing generic versions of Otezla during this period. The court validated U.S. Patent No. 7,427,638 and U.S. Patent No. 7,893,101 related to Otezla, while ruling against Amgen on U.S. Patent No. 10,092,541. Otezla is approved for treating plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's Disease.
Foresee Pharmaceuticals announced the appointment of Dr. Bassem Elmankabadi as Senior Vice President of Clinical Development on April 17, 2023. Dr. Elmankabadi brings over 17 years of clinical experience, previously holding leadership roles at Amgen (NASDAQ: AMGN) and FibroGen (NASDAQ: FGEN). His experience includes negotiating four Clinical Development Plans for Phase 2 and 3 studies for the company's drugs, Cudetaxestat and Pamrevlumab. Dr. Elmankabadi's background includes surgical leadership and clinical instruction at UCLA. Foresee Pharmaceuticals focuses on innovative therapies, with key products including CAMCEVI for advanced prostate cancer, approved in the U.S., Canada, and EU, as well as other promising candidates in clinical development.
